Prihlásiť sa Zaregistrujte sa zadarmo

SMA 200 spoločnosti Novabay Pharmaceuticals Inc

Aká je hodnota metriky SMA 200 spoločnosti Novabay Pharmaceuticals Inc?

Hodnota metriky SMA 200 spoločnosti Novabay Pharmaceuticals Inc je $7 -1,359.54%

Aká je definícia metriky SMA 200?



SMA 200 (Simple Moving Average 200) je priemerná cena akcie za posledných 200 dní vypočítaná ako nevážený priemer z predchádzajúcich 200 záverečných cien.

Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.

Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.

SMA 200 spoločností v sektore Health Care sektor na NYSEMKT v porovnaní so spoločnosťou Novabay Pharmaceuticals Inc

Čomu sa venuje spoločnosť Novabay Pharmaceuticals Inc?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Firmy s metrikou sma 200 podobnou spoločnosti Novabay Pharmaceuticals Inc